Lundbeck increased revenue and profits in 2010 after positive development in all regions.
Revenue increased by 7% to DKK 14,765 million and profits by 17% to DKK 3,357 million after Cipralex, Ebixa and Azilect showed strong growth and sales of Xenazine improved by 105%.
Ulf Wiinberg, Lundbeck’s President and CEO, said that 2010 had been “a year of progress”.
Long-term growth prospects also improved last year for Lundbeck as a result of six new partnership deals and positive Phase III data for three pipeline compounds.
“The good momentum is expected to continue for our marketed products, and several positive pipeline events and new partnerships allows for investments in commercialisation of a number of new products already in 2011,” said Ulf Wiinberg.
The Danish company now expects revenue to increase again to DKK 15,000 million but profits to fall to between DKK 2,300 and 2,600 million.
Share this article: